RxDoctor Payments Data

Vu Nguyen, DO

Family Medicine · Allentown, PANPI 1285627745

Payments from drug & device makers

$4,117in general payments, 2019–2025

Across 187 payments — averaging $22.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • AbbVie$770
  • Lilly USA, LLC$598
  • Musculoskeletal Transplant Foundation Inc.$309
  • Novo Nordisk$271
  • Boehringer Ingelheim$190
  • plus $917 from 19 others

What the payments were for

  • Food & beverage$4,07899%
  • Education$391%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,117 in reported general payments places this provider in the 85th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$10,822
Medicare patients
58
Services billed
118

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol19$27,103
MounjaroTirzepatide14$14,085
EliquisApixaban20$11,987
JanuviaSitagliptin Phosphate11$11,813
Rivastigmine12$3,473
Levocarnitine14$2,125
SynthroidLevothyroxine Sodium21$1,268
Armour ThyroidThyroid,pork13$1,169
Levothyroxine Sodium104$1,078
Albuterol Sulfate HfaAlbuterol Sulfate33$963
Omeprazole88$812
Pantoprazole Sodium18$576
Metoprolol Succinate42$566
Lisinopril92$544
Losartan Potassium52$516

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$1,062$27,10319 claims
Lilly USA, LLCMounjaro, Olanzapine$598$14,34245 claims
PfizerEliquis$137$11,98720 claims
AbbVieSynthroid, Armour Thyroid$770$2,43734 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Allentown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →